[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363587-105":59,"doc-detail-363587-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","evolving-antibody-drug-conjugates-in-breast-cancer-from-precision-delivery-to-tumor-microenvironment-reprogramming","Evolving antibody-drug conjugates in breast cancer - from precision delivery to tumor microenvironment reprogramming","","Antibody–drug conjugates (ADCs) are positioned as a key breast-cancer therapy, especially in the setting of molecular heterogeneity. The review tracks how ADCs evolved from targeted cytotoxic delivery toward multifunctional platforms that can shape the tumor microenvironment (TME). It discusses target expansion beyond HER2 to TROP-2 and HER3, links TME barriers to drug penetration and resistance, and outlines how immunogenic cell death can remodel immune status.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evolving-antibody-drug-conjugates-in-breast-cancer-from-precision-delivery-to-tumor-microenvironment-reprogramming/363587/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evolving-antibody-drug-conjugates-in-breast-cancer-from-precision-delivery-to-tumor-microenvironment-reprogramming/363587.png","ImageObject",300,407,{"name":92,"@type":93},"Jasmine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How did antibody–drug conjugates (ADCs) evolve in breast cancer therapy?","Question",{"text":112,"@type":113},"ADCs began as targeted cytotoxic delivery systems and are increasingly studied as multifunctional platforms that may also influence the tumor microenvironment (TME).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which ADC targets beyond HER2 are discussed, and why does it matter?",{"text":117,"@type":113},"Targets such as TROP-2 and HER3 expand therapeutic options, including for subtypes like triple-negative breast cancer (TNBC) with limited targeted therapies.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does the tumor microenvironment play in ADC efficacy and resistance?",{"text":121,"@type":113},"The review highlights that physical barriers, immunosuppressive signaling, and stromal interactions can limit drug penetration and therapeutic response. It also connects ADC-induced cytotoxicity with immunogenic cell death and remodeling of the tumor immune milieu.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363587,1790190678,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":14,"preview_urls":146},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Lu et al. Journal of Hematology & Oncology (2026) 19:38 [https://doi.org/10.1186/s13045-026-01799-2](https://doi.org/10.1186/s13045-026-01799-2)  \nJournal of Hematology & Oncology  \nREVIEW Open Access  \nEvolving antibody-drug conjugates in breast  cancer from precision delivery to tumor microenvironment reprogramming  \nNa Lu1, Bin Yan2, Yu-Qiang Li1 and Jing-Lei Wan2*  \nAbstract  \nAntibody–drug conjugates (ADCs) have emerged as an important therapeutic strategy for breast cancer, particularly in the context of its molecular heterogeneity. Initially developed as targeted cytotoxic delivery systems, ADCs are increasingly being explored as multifunctional platforms that may also influence the tumor microenvironment (TME) . The expansion of ADC targets beyond human epidermal growth factor receptor 2 (HER2) to include molecules such as trophoblast cell surface antigen 2 (TROP-2) and human epidermal growth factor receptor 3 (HER3) has broadened the therapeutic landscape, offering new options for subtypes with limited targeted therapies, including triple-negative breast cancer (TNBC) .  \nAccumulating evidence suggests that the tumor microenvironment plays a critical role in modulating ADC efficacy and resistance. Physical barriers, immunosuppressive signaling, and stromal interactions may limit drug penetration and therapeutic response. In parallel, ADC-induced cytotoxicity has been associated with immunogenic cell death and potential remodeling of the tumor immune milieu. These insights have prompted the development of improved ADC designs, including environment-responsive linkers, optimized payloads, and rational combination strategies with immunotherapy.  \nIn this review, we summarize the evolving landscape of ADC development in breast cancer, focusing on target expansion, structural optimization, resistance mechanisms, and interactions with the tumor microenvironment. We also discuss emerging strategies aimed at enhancing therapeutic efficacy and overcoming resistance, highlighting growing interest in integrating targeted cytotoxicity with modulation of the tumor microenvironment. Keywords Breast cancer, Antibody–drug conjugates, Tumor microenvironment, Precision delivery, Resistance mechanisms, Immune reprogramming, Immunotherapy  \n*Correspondence: Jing-Lei Wan [jlwan19@fudan.edu.cn](jlwan19@fudan.edu.cn)  \n1Department of Pathology, Jinan People’s Hospital Affiliated to Shandong First Medical University, Jinan 271199, Shandong, China  \n2Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nLu et al. Journal of Hematology & Oncology (2026) 19:38  \nIntroduction  \n1. Biological heterogeneity and therapeutic landscape of breast cancer  \nBreast cancer remains the most frequently diagnosed malignancy and a leading cause of cancer-rel","cbCaie4sHYY9tKq1","https://ap.wps.com/l/cbCaie4sHYY9tKq1","pdf",2096781,15,"English","# Abstract\n# Introduction\n## Biological heterogeneity and therapeutic landscape of breast cancer\n# Keywords\n# Correspondence","[{\"question\":\"How did antibody–drug conjugates (ADCs) evolve in breast cancer therapy?\",\"answer\":\"ADCs began as targeted cytotoxic delivery systems and are increasingly studied as multifunctional platforms that may also influence the tumor microenvironment (TME).\"},{\"question\":\"Which ADC targets beyond HER2 are discussed, and why does it matter?\",\"answer\":\"Targets such as TROP-2 and HER3 expand therapeutic options, including for subtypes like triple-negative breast cancer (TNBC) with limited targeted therapies.\"},{\"question\":\"What role does the tumor microenvironment play in ADC efficacy and resistance?\",\"answer\":\"The review highlights that physical barriers, immunosuppressive signaling, and stromal interactions can limit drug penetration and therapeutic response. It also connects ADC-induced cytotoxicity with immunogenic cell death and remodeling of the tumor immune milieu.\"}]","Evolving antibody-drug conjugates in breast cancer - from precision delivery to tumor microenvironment reprogramming | PDF",1790151978,38,[147,151],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/4cd1ae23f0125181b0be4922f8210585.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/9f5489d8a9fcff5fa2d0fa658d64dc85.webp",982,1309]